Heat Biologics, Inc. (HTBX): Price and Financial Metrics

Heat Biologics, Inc. (HTBX): $2.38

0.01 (+0.42%)

POWR Rating

Component Grades













Add HTBX to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where HTBX ranks best; there it ranks ahead of 56.15% of US stocks.
  • The strongest trend for HTBX is in Value, which has been heading up over the past 179 days.
  • HTBX ranks lowest in Momentum; there it ranks in the 4th percentile.

HTBX Stock Summary

  • HTBX's price/sales ratio is 38.24; that's higher than the P/S ratio of 95.38% of US stocks.
  • HTBX's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 6.66% of US stocks.
  • As for revenue growth, note that HTBX's revenue has grown -28.33% over the past 12 months; that beats the revenue growth of only 5.81% of US companies in our set.
  • Stocks that are quantitatively similar to HTBX, based on their financial statements, market capitalization, and price volatility, are CLSN, ABEO, HRTX, SDGR, and PSNL.
  • HTBX's SEC filings can be seen here. And to visit Heat Biologics Inc's official web site, go to www.heatbio.com.

HTBX Valuation Summary

  • In comparison to the median Healthcare stock, HTBX's price/sales ratio is 559.91% higher, now standing at 74.9.
  • HTBX's price/earnings ratio has moved up 4 over the prior 97 months.
  • HTBX's EV/EBIT ratio has moved up 10.9 over the prior 97 months.

Below are key valuation metrics over time for HTBX.

Stock Date P/S P/B P/E EV/EBIT
HTBX 2021-08-31 74.9 1.4 -6.2 -5.6
HTBX 2021-08-30 70.7 1.3 -5.9 -5.2
HTBX 2021-08-27 72.0 1.3 -6.0 -5.3
HTBX 2021-08-26 70.1 1.3 -5.8 -5.2
HTBX 2021-08-25 69.7 1.3 -5.8 -5.1
HTBX 2021-08-24 68.9 1.3 -5.7 -5.1

HTBX Growth Metrics

    Its 5 year net income to common stockholders growth rate is now at 1.68%.
  • Its 2 year net cashflow from operations growth rate is now at -102.23%.
  • Its 4 year price growth rate is now at -89.65%.
Over the past 52 months, HTBX's revenue has gone up $1,085,083.

The table below shows HTBX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 2.112806 -38.12891 -35.07147
2021-09-30 2.102898 -33.18167 -27.95969
2021-06-30 2.451063 -22.94841 -29.37858
2021-03-31 2.584734 -21.09049 -27.28981
2020-12-31 2.947969 -22.02136 -26.04974
2020-09-30 4.343893 -15.83093 -22.93477

HTBX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HTBX has a Quality Grade of D, ranking ahead of 6.36% of graded US stocks.
  • HTBX's asset turnover comes in at 0.018 -- ranking 373rd of 680 Pharmaceutical Products stocks.
  • ALNY, TXMD, and ENTA are the stocks whose asset turnover ratios are most correlated with HTBX.

The table below shows HTBX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.018 1 -0.270
2021-03-31 0.023 1 -0.309
2020-12-31 0.034 1 -0.411
2020-09-30 0.069 1 -0.602
2020-06-30 0.096 1 -1.360
2020-03-31 0.110 1 -2.217

HTBX Price Target

For more insight on analysts targets of HTBX, see our HTBX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.5 (Moderate Buy)

HTBX Stock Price Chart Interactive Chart >

Price chart for HTBX

HTBX Price/Volume Stats

Current price $2.38 52-week high $10.85
Prev. close $2.37 52-week low $2.07
Day low $2.33 Volume 43,600
Day high $2.48 Avg. volume 171,558
50-day MA $2.65 Dividend yield N/A
200-day MA $4.38 Market Cap 61.05M

Heat Biologics, Inc. (HTBX) Company Bio

Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC.

HTBX Latest News Stream

Event/Time News Detail
Loading, please wait...

HTBX Latest Social Stream

Loading social stream, please wait...

View Full HTBX Social Stream

Latest HTBX News From Around the Web

Below are the latest news stories about Heat Biologics Inc that investors may wish to consider to help them evaluate HTBX as an investment opportunity.

Morrisville firm targeting biothreats will leave the Nasdaq; new subsidiary scores $81M contract

The future subsidiary of a Triangle drugmaker has scored a federal contract potentially worth up to roughly $81 million. Meanwhile, the company is preparing to leave the Nasdaq for another stock exchange.

Yahoo | February 9, 2022

Heat Biologics to move to NYSE from Nasdaq

Heat Biologics (HTBX) said it plans to change its listing to the NYSE American stock exchange from from the Nasdaq Capital Market.Heat expects to begin trading on NYSE under its

Seeking Alpha | February 2, 2022

Heat Biologics Announces Planned Transfer to the NYSE American

DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, announced today that it plans to change its listing from the Nasdaq Capital Market to the NYSE American stock exchange. “We are pleased to announce our listing on the NYSE American, a global leader in listings for a range of sectors, including life sciences and technology,” said Jeff

Yahoo | February 2, 2022

Heat Biologics rises 10% as Elusys finalizes HHS contract for anthrax antitoxin Anthim

Elusys Therapeutics, which is being acquired by Heat Biologics <>, said it finalized a contract with the U.S

Seeking Alpha | January 31, 2022

Heat Biologics' Merger Partner Elusys Finalizes HHS Contract For Its Anthrax Treatment

Elusys Therapeutics Inc, the merger partner for Heat Biologics Inc (NASDAQ: HTBX), has finalized a contract with the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the U.S. Department of Health and Human Services (HHS) for the continued supply of ANTHIM (obiltoxaximab), an anthrax antitoxin. The contract for ANTHIM consists of a base period of performance, valued at $50 million, which is fulfilled. The contract includes options valued at up to $31 million. If all optio

Yahoo | January 31, 2022

Read More 'HTBX' Stories Here

HTBX Price Returns

1-mo N/A
3-mo -22.22%
6-mo -21.71%
1-year -65.26%
3-year -50.36%
5-year -94.43%
YTD -21.71%
2021 -43.28%
2020 61.20%
2019 -51.53%
2018 -74.41%
2017 -55.47%

Continue Researching HTBX

Here are a few links from around the web to help you further your research on Heat Biologics Inc's stock as an investment opportunity:

Heat Biologics Inc (HTBX) Stock Price | Nasdaq
Heat Biologics Inc (HTBX) Stock Quote, History and News - Yahoo Finance
Heat Biologics Inc (HTBX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5819 seconds.